G.R.I.N ULTRA

G.R.I.N Ultra is an Israeli biotechnology company and a wholly owned subsidiary of CNBX Pharmaceuticals (formerly Cannabics Pharmaceuticals). The company specializes in the development of personalized cannabinoid-based therapies for cancer and palliative care, leveraging a proprietary high-throughput screening (HTS) platform. This platform allows for the testing of various cannabinoid combinations against patient-derived cancer biopsies to identify the most effective anti-tumor formulations. G.R.I.N Ultra's lead clinical candidate, Cannabics SR, is being developed for the treatment of cancer anorexia-cachexia syndrome (CACS), while its preclinical candidate, RCC-33, targets colorectal cancer. The company operates under a research license from the Israeli Ministry of Health and integrates bioinformatics and AI to optimize its drug discovery process.